Common Adverse Effects of Anti-TNF Agents on Gestation
Autoimmune disease has affected up to 50 million Americans, according to the American Autoimmune Related Diseases Association (AARDA) and 75 percent of those affected are women. These inflammatory diseases have variable activity and a lot of women will have to undergo major therapies during and afte...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Obstetrics and Gynecology International |
| Online Access: | http://dx.doi.org/10.1155/2016/8648651 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558823428063232 |
|---|---|
| author | Zacharias Fasoulakis Panagiotis Antsaklis Nikolaos Galanopoulos Emmanuel Kontomanolis |
| author_facet | Zacharias Fasoulakis Panagiotis Antsaklis Nikolaos Galanopoulos Emmanuel Kontomanolis |
| author_sort | Zacharias Fasoulakis |
| collection | DOAJ |
| description | Autoimmune disease has affected up to 50 million Americans, according to the American Autoimmune Related Diseases Association (AARDA) and 75 percent of those affected are women. These inflammatory diseases have variable activity and a lot of women will have to undergo major therapies during and after pregnancy. Many of the women suffering from these disease will improve during gestation. However a lot of women will require continuation of disease-modifying therapies (i.e., biological therapies) throughout pregnancy and post-partum involving many risks. In the past decade all gaze turned to biological therapies, as an attempt, to obtain even more effective medications in order to suppress the exacerbation of autoimmune disease, even at the most unfit circumstances such as pregnancy. The results are both satisfying and promising since increasingly proven thoughts prevail on making anti-TNF agents first-line medications, clearing up the limited knowledge over human influence. The purpose of this review is to summarize the results of the reports with the highest and representative range of patients of the last decade involving the use of anti-TNF agents during pregnancy. |
| format | Article |
| id | doaj-art-b465319f97ee4d1f8cc79160f4b3eb5c |
| institution | Kabale University |
| issn | 1687-9589 1687-9597 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Obstetrics and Gynecology International |
| spelling | doaj-art-b465319f97ee4d1f8cc79160f4b3eb5c2025-02-03T01:31:32ZengWileyObstetrics and Gynecology International1687-95891687-95972016-01-01201610.1155/2016/86486518648651Common Adverse Effects of Anti-TNF Agents on GestationZacharias Fasoulakis0Panagiotis Antsaklis1Nikolaos Galanopoulos2Emmanuel Kontomanolis3Department of Obstetrics & Gynecology, Democritus University of Thrace, Alexandroupolis, Greece1st Department of Obstetrics & Gynecology, University of Athens, Athens, GreeceState Clinic of Rheumatology, Democritus University of Thrace, Alexandroupolis, GreeceDepartment of Obstetrics & Gynecology, Democritus University of Thrace, Alexandroupolis, GreeceAutoimmune disease has affected up to 50 million Americans, according to the American Autoimmune Related Diseases Association (AARDA) and 75 percent of those affected are women. These inflammatory diseases have variable activity and a lot of women will have to undergo major therapies during and after pregnancy. Many of the women suffering from these disease will improve during gestation. However a lot of women will require continuation of disease-modifying therapies (i.e., biological therapies) throughout pregnancy and post-partum involving many risks. In the past decade all gaze turned to biological therapies, as an attempt, to obtain even more effective medications in order to suppress the exacerbation of autoimmune disease, even at the most unfit circumstances such as pregnancy. The results are both satisfying and promising since increasingly proven thoughts prevail on making anti-TNF agents first-line medications, clearing up the limited knowledge over human influence. The purpose of this review is to summarize the results of the reports with the highest and representative range of patients of the last decade involving the use of anti-TNF agents during pregnancy.http://dx.doi.org/10.1155/2016/8648651 |
| spellingShingle | Zacharias Fasoulakis Panagiotis Antsaklis Nikolaos Galanopoulos Emmanuel Kontomanolis Common Adverse Effects of Anti-TNF Agents on Gestation Obstetrics and Gynecology International |
| title | Common Adverse Effects of Anti-TNF Agents on Gestation |
| title_full | Common Adverse Effects of Anti-TNF Agents on Gestation |
| title_fullStr | Common Adverse Effects of Anti-TNF Agents on Gestation |
| title_full_unstemmed | Common Adverse Effects of Anti-TNF Agents on Gestation |
| title_short | Common Adverse Effects of Anti-TNF Agents on Gestation |
| title_sort | common adverse effects of anti tnf agents on gestation |
| url | http://dx.doi.org/10.1155/2016/8648651 |
| work_keys_str_mv | AT zachariasfasoulakis commonadverseeffectsofantitnfagentsongestation AT panagiotisantsaklis commonadverseeffectsofantitnfagentsongestation AT nikolaosgalanopoulos commonadverseeffectsofantitnfagentsongestation AT emmanuelkontomanolis commonadverseeffectsofantitnfagentsongestation |